ArticleScientific reports2025
Engineering PVX vectors harboring heterologous VSRs to enhance Recombinant vaccine protein expression in plants.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transforming Plant Viruses into Vectors for Next-Generation Agriculture-A Review.Current microbiology · 2026Review
- Plant Viral Vectors for Vaccine Development.Vaccines · 2026Review
- Viral vectors for antimicrobial peptide expression: a new path for crop protection.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-based systems offer a sustainable platform for production of recombinant proteins, but their utility remains limited by host RNA silencing and low yields. Potato virus X (PVX)-derived vectors have shown promise in transient expression systems; however, their efficiency can be further improved by incorporating viral suppressors of RNA silencing (VSRs). Here, we engineered optimized PVX-based expression vectors harboring heterologous VSRs (P19, P38, and NSs) from distinct plant viruses, systematically evaluating the effects of VSR type, insertion position, and transcriptional orientation. Reversing the VSR cassette orientation relative to the target gene alleviated transcriptional interference, significantly improving both target protein and VSR expression. Among the tested VSRs, NSs conferred the highest expression, followed closely by P38. The best-performing pP3-based vectors achieved GFP accumulation of up to 0.50 mg/g fresh weight (FW), representing a 3 ~ 4-fold increase compared to the parental PVX vector (0.13 mg/g FW). For vaccine antigens, maximum yields reached 0.016 mg/g FW for VP1 and 0.017 mg/g FW for S2, exceeding the parental vectors' yields by over 100-fold. These findings highlight the potential of integrating VSRs into PVX-derived vectors to enhance transient expression of recombinant proteins in Nicotiana benthamiana, providing a robust platform for vaccine antigen production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.